Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Subsequent Events

11. Subsequent Events

On August 15, 2012, August 6, 2012, and July 20, 2012 we and TPL each contributed $86,750, $450,000, and $50,000, respectively, to PDS. F-28

Does this fall under certain allocations or certain additional allocations pursuant to the new agreements with TPL/Alliacense/PDS?

http://www.sec.gov/Archives/edgar/data/836564/000101968712003037/ptsc_10k-053112.htm

Share
New Message
Please login to post a reply